Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Downreguation of FoxM1 by miR-214 inhibits proliferation and migration in hepatocellular carcinoma

Gene Therapy volume 25, pages 312–319 (2018)Cite this article

Subjects

Abstract

The FoxM1 transcription factor plays an important role in the progression of HCC. Therefore, it is necessary to study cell regulation of FoxM1. In this study, we determined the expression of miR-214 and it was inversely associated with FoxM1 protein level in HCC; and suppression of FoxM1 translation by miR-214 mimics. We found that miR-214 targeted the 3′untranslated region of FoxM1 mRNA. In addition, the study found that DLX1 was the direct target of FoxM1 in HCC. Downregulation of FoxM1 inhibits the proliferation, migration, and invasion of HCC cells by miR-214. These results indicate that miR-214 may be used as a completely new molecular target by influencing FoxM1 expression in HCC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

    Article  PubMed  Google Scholar 

  2. Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, et al. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int. 2016;36:1196–205.

    Article  CAS  PubMed  Google Scholar 

  3. Zhang X, Zhang L, Du Y, Zheng H, Zhang P, Sun Y, et al. A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer. Oncogene. 2017;36:807–19.

    Article  CAS  PubMed  Google Scholar 

  4. Yan Chen,Yifei Liu, Haosheng Ni, Chuanjin Ding, Xiaobo Zhang, Zhenxin Zhang, et al. FoxM1 overexpression promotes cell proliferation and migration and inhibits apoptosis in hypopharyngeal squamous cell carcinoma resulting in poor clinical prognosis. Int. J. Oncol. 2017; 51(4):1045-1054.

  5. John Le Lay, Klaus H Kaestner. The Fox genes in the liver: from organogenesis tofunctional integration. Physiol. Rev. 2010; 90(1)1-22.

  6. Artem Smirnov, Emanuele Panatta, AnnaMaria Lena, Daniele Castiglia, Nicola DiDaniele, Gerry Melino,et al. Aging (Albany NY) 2016; 8(7):1384-97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Guanghong Xiu, Xiujie Sui, Yirong Wang, Ze Zhang. FOXM1 regulates radiosensitivity of lung cancer cell partly by upregulating KIF20A. Eur. J. Pharmacol. 2018; 83379-85.

  8. Kiselev FL. MicroRNA and cancer. Mol Biol. 2014;48:232–42.

    CAS  Google Scholar 

  9. Zu Y, Yang Y, Zhu J, Bo X, Hou S, Zhang B, et al. MiR-146a suppresses hepatocellular carcinoma by downregulating TRAF6. Am J Cancer Res. 2016;6:2502–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Chen H, Liu C, Jiang H, Gao Y, Xu M, Wang J, et al. Regulatory role of miRNA-375 in expression of BMP15/GDF9 receptors and its effect on proliferation and apoptosis of bovine cumulus cells. Cell Physiol Biochem. 2017;41:439–50.

    Article  CAS  PubMed  Google Scholar 

  11. Hartig SM, Hamilton MP, Bader DA, McGuire SE. The miRNA interactome in metabolic homeostasis. Trends Endocrinol Metab. 2015;26:733–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Xiaoyan Liu, Lei Bi, Qin Wang, Mingxin Wen, Ce Li, Yidan Ren, Qinlian Jiao, et al. miR-1204 targets VDR to promotes epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene 2018; 37(25):3426-3439.

    Article  CAS  PubMed  Google Scholar 

  13. Cristobal I, Carames C, Madoz-Gurpide J, Rojo F, Aguilera O, Garcia-Foncillas J. Downregulation of miR-214 is specific of liver metastasis in colorectal cancer and could play a role determining the metastatic niche. Int J Colorectal Dis. 2014;29:885.

    Article  PubMed  Google Scholar 

  14. Guo J, Ma J, Zhao G, Li G, Fu Y, Luo Y, Long Non-Coding RNA. LINC0086 functions as a tumor suppressor in nasopharyngeal carcinoma by targeting miR-214. Oncol Res. 2017;25:1189–97.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Liu WH, Chen CH, Yeh KH, Li CL, Wu YJ, Chen DS, et al. ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers. PLoS ONE. 2013;8:e81922.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chan DW, Hui WW, Wang JJ, Yung MM, Hui LM, Qin Y et al. DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-beta/SMAD4 signaling. Oncogene 2017; 36(10):1404-1416.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Jian-Mei Wang, Bao-Hui Ju, Cai-Jun Pan, Yan Gu, Meng-Qi Li, Li Sun, et al. MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1. Am J Transl Res 2017; 9(8):3541-3557.

  18. Zhu XB, Zhang ZC, Han GS, Han JZ, Qiu DP. Overexpression of miR214 promotes the progression of human osteosarcoma by regulating the Wnt/betacatenin signaling pathway. Mol Med Rep. 2017;15:1884–92.

    Article  CAS  PubMed  Google Scholar 

  19. Liao J, Lin J, Lin D, Zou C, Kurata J, Lin R, et al. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression. Sci Rep. 2017;7:781.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Li TK, Yin K, Chen Z, Bao Y, Zhang SX. MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5. Genet Mol Res. 2017 Mar 8;16(1).

  21. Liu B, Tian Y, Li F, Zhao Z, Jiang X, Zhai C, et al. Tumor-suppressing roles of miR-214 and miR-218 in breast cancer. Oncol Rep. 2016;35:3178–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Xin R, Bai F, Feng Y, Jiu M, Liu X, Bai F, et al. MicroRNA-214 promotes peritoneal metastasis through regulating PTEN negatively in gastric cancer. Clin Res Hepatol Gastroenterol. 2016;40:748–54.

    Article  CAS  PubMed  Google Scholar 

  23. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008;27:5959–74.

    Article  CAS  PubMed  Google Scholar 

  24. Wang J, Zhou M, Wang X, Yang X, Wang M, Zhang C, et al. Impact of ketamine on learning and memory function, neuronal apoptosis and its potential association with miR-214 and PTEN in adolescent rats. PLoS ONE. 2014;9:e99855.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, et al. MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 2009;61:1075–82.

    Article  CAS  PubMed  Google Scholar 

  26. Gao M, Liu Y, Chen Y, Yin C, Chen JJ, Liu S. miR-214 protects erythroid cells against oxidative stress by targeting ATF4 and EZH2. Free Radic Biol Med. 2016;92:39–49.

    Article  CAS  PubMed  Google Scholar 

  27. Tian X, Zeng G, Li X, Wu Z, Wang L. Cantharidin inhibits cell proliferation and promotes apoptosis in tongue squamous cell carcinoma through suppression of miR-214 and regulation of p53 and Bcl-2/Bax. Oncol Rep. 2015;33:3061–8.

    Article  CAS  PubMed  Google Scholar 

  28. Zhenfeng Zhang, Pengfei Ma, Ying Jing, Ying Yan, Mei-Chun Cai, Meiying Zhang, et al. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. Theranostics 2016; 6(2):219-30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kang JG, Majerciak V, Uldrick TS, Wang X, Kruhlak M, Yarchoan R, et al. Kaposi’s sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. J Pathol. 2011;225:378–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zheng WW, Zhou J, Zhang CH, Liu XS. MicroRNA-216b is downregulated in hepatocellular carcinoma and inhibits HepG2 cell growth by targeting Forkhead box protein M1. Eur Rev Med Pharmacol Sci. 2016;20:2541–50.

    PubMed  Google Scholar 

  31. Meng FD, Wei JC, Qu K, Wang ZX, Wu QF, Tai MH, et al. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma. World J Gastroenterol. 2015;21:196–213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wei JC, Meng FD, Qu K, Wang ZX, Wu QF, Zhang LQ, et al. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. Acta Pharmacol Sin. 2015;36:241–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Qu K, Xu X, Liu C, Wu Q, Wei J, Meng F, et al. Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma. Cancer Lett. 2013;331:105–14.

    Article  CAS  PubMed  Google Scholar 

  34. Dai X, Iwasaki H, Watanabe M, Okabe S. DLX1 transcription factor regulates dendritic growth and postsynaptic differentiation through inhibition of neuropilin-2 and PAK3 expression. Eur J Neurosci. 2014;39:531–47.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work is supported by the Science and Technology Foundation of the Health and Family Planning Commission of Guizhou province, China (gzwjkj2017-1-005).

Author information

Author notes

    Authors and Affiliations

    1. Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, 210002, Nanjing, Jiangsu, China

      Chuan Tian

    2. Department of Oncology, Guizhou Provincial People’s Hospital, 550002, Guiyang, Guizhou, China

      Chuan Tian, Haixia Wu & Xia Tian

    3. Department of Hematology, Heji Hospital Affiliated to Changzhi Medical College, 046000, Changzhi, Shanxi, China

      Chan Li

    4. Department of General Surgery, People’s Hospital of YanHe, 554300, Tongren, Guizhou, China

      Yong Sun

    5. Department of Oncology, Qianjiang Central Hospital of Chongqing Municipality, Qianjiang, 409000, Chongqing, China

      Enqiang Liu & Xiuyong Liao

    6. Department of Intervention and Vascular Surgery, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou Cancer Treatment Center, 215000, Suzhou, Jiangsu, China

      Wei Song

    Authors
    1. Chuan Tian
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Haixia Wu
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Chan Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Xia Tian
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Yong Sun
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Enqiang Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Xiuyong Liao
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Wei Song
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Wei Song.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Additional information

    These authors contributed equally: Chuan Tian, Haixia Wu, Chan Li.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Tian, C., Wu, H., Li, C. et al. Downreguation of FoxM1 by miR-214 inhibits proliferation and migration in hepatocellular carcinoma. Gene Ther 25, 312–319 (2018). https://doi.org/10.1038/s41434-018-0029-4

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1038/s41434-018-0029-4

    This article is cited by

    Search

    Advanced search

    Quick links